TY - JOUR
T1 - Brain health INnovation Diplomacy
T2 - A model binding diverse disciplines to manage the promise and perils of technological innovation
AU - Ternes, Kylie
AU - Iyengar, Vijeth
AU - Lavretsky, Helen
AU - Dawson, Walter D.
AU - Booi, Laura
AU - Ibanez, Agustin
AU - Vahia, Ipsit
AU - Reynolds, Charles
AU - Dekosky, Steven
AU - Cummings, Jeffrey
AU - Miller, Bruce
AU - Perissinotto, Carla
AU - Kaye, Jeffrey
AU - Eyre, Harris A.
N1 - Funding Information:
HL reported grant support by NIH grant AT009198. JC was supported by KMA and NIGMS grant P20GM109025. SD reported grant support from NIA AG047266 and the Ed and Ethel Moore Alzheimers Disease Research Program, State of Florida. AI was partially supported by grants GBHI ALZ UK-20-639295, NIH/NIA R01 AG057234, CONICET, FONCYT-PICT (2017-1818, 2017-1820), CONICYT/FONDECYT Regular (1170010), FONDAP 15150012, the INECO Foundation, and the Interamerican Development Bank. JK reported grants including the following from NIH: U2C AG054397, P30 AG008017, P30 AG024978, R01 AG051628, R01 AG051628, U01 AG010483, Merck Investigator Study Program.
Funding Information:
HE reports ownership of shares in CNSdose LLC. HL has a research grant from Allergan. JC has provided consultation to Acadia, Actinogen, Alkahest, Allergan, Alzheon, Avanir, Axsome, BiOasis, Biogen, Bracket, Cassava, Cerecin, Cortexyme, EIP Pharma, Eisai, Foresight, Genentech, Green Valley, Grifols, Hisun, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Takeda, Third Rock, Toyama, and United Neuroscience pharmaceutical and assessment companies. SD reports consultation for Amgen, Acumen, Biogen, Cognition Therapeutics. WD reports ownership of shares in Insights to Illuminate LLC. IV receives research funding from the Once Upon a Time Foundation. JK receives research support from the NIH (U2C AG054397, P30 AG008017, P30 AG024978, R01 AG051628, R01 AG051628, U01 AG010483) and Merck; directs centers at Oregon Health & Science University that receives research support from the NIH, CDC, National Science Foundation, the Department of Veterans Affairs, AbbVie, Novartis, Kyowa, Glovia, and Eisai; is (or has been in the last 36 months) compensated for serving on Data Safety Monitoring Committees for Eli Lilly and Suven; is compensated for serving on the Scientific Advisory Board for Sage Bionetworks; receives reimbursement through Medicare or commercial insurance plans for providing clinical assessment and care for patients; and serves on the editorial advisory board and as Associate Editor of the journal, Alzheimer’s & Dementia and as Associate Editor for the Journal of Translational Engineering in Health and Medicine. The other authors have no conflicts of interest to declare.
Funding Information:
Supporting global health technology development is the newly established Global Health Technologies Coalition (GHTC) (GHTC, ). The GHTC is an advocacy organization, funded by the Bill and Melinda Gates Foundation, focused on global health, research, and development for new tools and technologies. The coalition of more than 25 nonprofit organizations, academic institutions, and aligned businesses advances policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools. The GHTC educates policymakers and stakeholders and convenes members and partners to facilitate innovation and advocacy for policy solutions and investment to spur innovation. This may be a useful platform for brain health innovation.
Publisher Copyright:
© 2020 International Psychogeriatric Association.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: Brain health diplomacy aims to influence the global policy environment for brain health (i.e. dementia, depression, and other mind/brain disorders) and bridges the disciplines of global brain health, international affairs, management, law, and economics. Determinants of brain health include educational attainment, diet, access to health care, physical activity, social support, and environmental exposures, as well as chronic brain disorders and treatment. Global challenges associated with these determinants include large-scale conflicts and consequent mass migration, chemical contaminants, air quality, socioeconomic status, climate change, and global population aging. Given the rapidly advancing technological innovations impacting brain health, it is paramount to optimize the benefits and mitigate the drawbacks of such technologies.Objective: We propose a working model of Brain health INnovation Diplomacy (BIND).Methods: We prepared a selective review using literature searches of studies pertaining to brain health technological innovation and diplomacy.Results: BIND aims to improve global brain health outcomes by leveraging technological innovation, entrepreneurship, and innovation diplomacy. It acknowledges the key role that technology, entrepreneurship, and digitization play and will increasingly play in the future of brain health for individuals and societies alike. It strengthens the positive role of novel solutions, recognizes and works to manage both real and potential risks of digital platforms. It is recognition of the political, ethical, cultural, and economic influences that brain health technological innovation and entrepreneurship can have.Conclusions: By creating a framework for BIND, we can use this to ensure a systematic model for the use of technology to optimize brain health.
AB - Background: Brain health diplomacy aims to influence the global policy environment for brain health (i.e. dementia, depression, and other mind/brain disorders) and bridges the disciplines of global brain health, international affairs, management, law, and economics. Determinants of brain health include educational attainment, diet, access to health care, physical activity, social support, and environmental exposures, as well as chronic brain disorders and treatment. Global challenges associated with these determinants include large-scale conflicts and consequent mass migration, chemical contaminants, air quality, socioeconomic status, climate change, and global population aging. Given the rapidly advancing technological innovations impacting brain health, it is paramount to optimize the benefits and mitigate the drawbacks of such technologies.Objective: We propose a working model of Brain health INnovation Diplomacy (BIND).Methods: We prepared a selective review using literature searches of studies pertaining to brain health technological innovation and diplomacy.Results: BIND aims to improve global brain health outcomes by leveraging technological innovation, entrepreneurship, and innovation diplomacy. It acknowledges the key role that technology, entrepreneurship, and digitization play and will increasingly play in the future of brain health for individuals and societies alike. It strengthens the positive role of novel solutions, recognizes and works to manage both real and potential risks of digital platforms. It is recognition of the political, ethical, cultural, and economic influences that brain health technological innovation and entrepreneurship can have.Conclusions: By creating a framework for BIND, we can use this to ensure a systematic model for the use of technology to optimize brain health.
KW - Alzheimer's
KW - Brain health
KW - dementia
KW - depression
KW - diplomacy
KW - entrepreneurship
KW - innovation
KW - technology
UR - http://www.scopus.com/inward/record.url?scp=85079412648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079412648&partnerID=8YFLogxK
U2 - 10.1017/S1041610219002266
DO - 10.1017/S1041610219002266
M3 - Review article
C2 - 32019621
AN - SCOPUS:85079412648
SN - 1041-6102
VL - 32
SP - 955
EP - 979
JO - International Psychogeriatrics
JF - International Psychogeriatrics
IS - 8
ER -